Cubist Systematic Strategies LLC Has $689,000 Stock Position in Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Cubist Systematic Strategies LLC increased its stake in Y-mAbs Therapeutics by 223.9%, owning 155,522 shares worth $689,000 as of its latest SEC filing.
• Y-mAbs Therapeutics reported a quarterly loss of ($0.07) EPS, exceeding analyst expectations, with revenue of $19.52 million despite a net margin of -26.03%.
• Several analysts have downgraded Y-mAbs stock ratings to "hold" and set a price target of $8.60, with an average target price of $9.62 across analysts.

Cubist Systematic Strategies LLC increased its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 223.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 155,522 shares of the company's stock after purchasing an additional 107,511 shares during the quarter. Cubist Systematic Strategies LLC owned 0.34% of Y-mAbs Therapeutics worth $689,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in YMAB. Stonepine Capital Management LLC acquired a new stake in Y-mAbs Therapeutics in the first quarter worth $581,000. Jump Financial LLC increased its position in Y-mAbs Therapeutics by 14.1% in the first quarter. Jump Financial LLC now owns 38,079 shares of the company's stock worth $169,000 after buying an additional 4,699 shares during the period. AlphaQuest LLC increased its position in Y-mAbs Therapeutics by 43.4% in the first quarter. AlphaQuest LLC now owns 38,925 shares of the company's stock worth $172,000 after buying an additional 11,790 shares during the period. EntryPoint Capital LLC acquired a new stake in Y-mAbs Therapeutics in the first quarter worth $56,000. Finally, Wellington Management Group LLP increased its position in Y-mAbs Therapeutics by 53.1% in the first quarter. Wellington Management Group LLP now owns 204,052 shares of the company's stock worth $904,000 after buying an additional 70,789 shares during the period. 70.85% of the stock is currently owned by institutional investors.

Y-mAbs Therapeutics Trading Up 0.2%

YMAB stock traded up $0.02 during trading hours on Monday, hitting $8.61. 760,675 shares of the stock traded hands, compared to its average volume of 836,547. The stock has a 50-day simple moving average of $6.93 and a 200 day simple moving average of $5.40. Y-mAbs Therapeutics, Inc. has a one year low of $3.55 and a one year high of $16.11. The company has a market cap of $391.24 million, a P/E ratio of -17.22 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Friday, August 8th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.20. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%.The business had revenue of $19.52 million during the quarter, compared to analysts' expectations of $18.40 million. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Jones Trading lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Brookline Capital Management lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 5th. Oppenheimer lowered Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Tuesday, August 5th. HC Wainwright reissued a "neutral" rating and set a $8.60 price target (down from $11.00) on shares of Y-mAbs Therapeutics in a report on Wednesday, August 6th. Finally, Cantor Fitzgerald set a $8.60 price target on Y-mAbs Therapeutics and gave the company a "neutral" rating in a report on Tuesday, August 5th. Eight analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Y-mAbs Therapeutics has a consensus rating of "Reduce" and an average price target of $9.62.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.